findmyKOL
Clinical trialNCT05526989RecruitingPhase 2Interventional

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment25Penile Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Moffitt Cancer Center

    Tampa, Florida, United States

    Jingsong Zhang, MD, PhDJuskaran Chadha, DOMonica Chatwal, MD
    Recruiting
  • Md Anderson Cancer Center

    Houston, Texas, United States

    Curtis Pettaway, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dostarlimab →Niraparib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
28 Dec 2022
Primary completion
30 Nov 2026
Completion
30 Nov 2027
Last update posted
4 Dec 2025
Registered enrollment
25
Registry id
NCT05526989
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.